Shots:

• The approval is based on two P-III studies: The SAkuraStar & SAkuraSky studies involves assessing Enspryng as monothx.  and in combination with IST vs PBO in 95 & 83 NMOSD patients who are AQP4 seropositive aged 18-74yrs. & 12-74yrs. respectively
• SAkuraStar & SAkuraSky results: 74% & 79% reduction in the risk of relapses respectively
• Enspryng (SC- q4w) is a mAb targeting IL-6R treatment. Additionally- Canada is the first country to receive health authority approval for Enspryng- offering a new treatment option for NMOSD  

­ Ref: Newswire Canada | Image: Roche